Zobrazeno 1 - 10
of 45
pro vyhledávání: '"J Hirshfield-Bartek"'
Autor:
Emily Schlosnagle, Laura S. Dominici, Faina Nakhlis, J Hirshfield-Bartek, Meredith M. Regan, Beth T. Harrison, AH Partridge, A Morikawa, Jennifer R. Bellon, Rachel A. Freedman, Nu Lin, Beth Overmoyer, EP Winer, DE Morganstern, Jiani Hu
Publikováno v:
Cancer Research. 78:P6-15
Background: Inflammatory breast cancer (IBC) is inoperable at presentation, thus neoadjuvant systemic therapy (NAS) is the primary treatment for this aggressive disease. Due to its rarity, patients (pts) with IBC are incorporated into NAS clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::729b5aabed2699000e41a8044a254632
https://doi.org/10.1158/1538-7445.sabcs17-p6-15-11
https://doi.org/10.1158/1538-7445.sabcs17-p6-15-11
Autor:
Eren D. Yeh, Erin E. Mullaney, Beth Overmoyer, Margaret M. Duggan, Laura S. Dominici, Meredith M. Regan, Jennifer R. Bellon, J Hirshfield-Bartek, Laura E.G. Warren, Mehra Golshan, Heather A. Jacene, Faina Nakhlis
Publikováno v:
Annals of Surgical Oncology. 24:2563-2569
Inflammatory breast cancer (IBC) is a rare and aggressive disease treated with multimodality therapy: preoperative systemic therapy (PST) followed by modified radical mastectomy (MRM), chest wall and regional nodal radiotherapy, and adjuvant biologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b170967b6cc30dc36f8dc73e18cf89e
https://doi.org/10.1245/s10434-017-5903-6
https://doi.org/10.1245/s10434-017-5903-6
Autor:
Nu Lin, Katya Losk, Mehra Golshan, L Cutone, Craig A. Bunnell, J Hirshfield-Bartek, Kristen Camuso, Sarah Kadish, Maxwell R. Lloyd, I Vaz Duarte Luis
Publikováno v:
Cancer Research. 76:P1-12
Background: National guidelines endorse time-dependent quality metrics for breast cancer care. We examined factors associated with delays in chemotherapy initiation at an NCI designated comprehensive cancer center. Methods: We identified 523 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e17b48521534927ede38e3b397983156
https://doi.org/10.1158/1538-7445.sabcs15-p1-12-08
https://doi.org/10.1158/1538-7445.sabcs15-p1-12-08
Autor:
Heather A. Jacene, Faina Nakhlis, Meredith M. Regan, Yoon S. Chun, Aditi Hazra, J Hirshfield-Bartek, Eren D. Yeh, Beth Overmoyer, Jennifer R. Bellon, Kelly A. Hirko, Laura E.G. Warren, Laura S. Dominici
Publikováno v:
Cancer Research. 76:P6-18
Background Inflammatory Breast Cancer (IBC) is a rare and aggressive type of breast cancer treated by multimodality therapy. Due to the presence of dermal lymphatic involvement by disease it is unknown whether a skin sparing mastectomy (SSM) would be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::174fa93358eba050e1cef90e1b2c47aa
https://doi.org/10.1158/1538-7445.sabcs15-p6-18-02
https://doi.org/10.1158/1538-7445.sabcs15-p6-18-02
Autor:
Jennifer R. Bellon, Faina Nakhlis, Emily Schlosnagle, Aditi Hazra, Kelly A. Hirko, Eren D. Yeh, Laura S. Dominici, Beth Overmoyer, Heather A. Jacene, J Hirshfield-Bartek, Laura E.G. Warren
Publikováno v:
Cancer Research. 76:P6-18
Introduction: Inflammatory breast cancer (IBC) is a rare and highly lethal form of breast cancer, accounting for approximately 10% of breast cancer mortality in the US. The clinical presentation of IBC includes rapid onset of symptoms, erythema > 1/3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ae1cb9c4d905529481df981f1cf81c9
https://doi.org/10.1158/1538-7445.sabcs15-p6-18-03
https://doi.org/10.1158/1538-7445.sabcs15-p6-18-03
Autor:
Randie E White, Heather A. Jacene, Eren D. Yeh, Beth Overmoyer, J Hirshfield-Bartek, Jennifer R. Bellon, Faina Nakhlis, Laura E.G. Warren
Publikováno v:
Cancer Research. 75:P6-14
Introduction: Inflammatory breast cancer (IBC) is a virulent form of breast cancer, characterized by skin erythema and edema associated with enlargement of the breast rapidly occurring within 3-6 months (mo). Because of its rarity ( Methods: This stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::002663fc4aad713f75e930c6195a0b24
https://doi.org/10.1158/1538-7445.sabcs14-p6-14-08
https://doi.org/10.1158/1538-7445.sabcs14-p6-14-08
Autor:
J Hirshfield-Bartek, Saul N. Weingart, Craig A. Bunnell, Sarah Kadish, Mehra Golshan, Katya Losk, Fatih Aydogan, Yasuaki Sagara, Linda Cutone, Nan Lin, Kristen Camuso
Publikováno v:
Breast Cancer Research and Treatment. 148:125-133
Few studies have examined care processes within providers’ and institutions’ control that expedite or delay care. The authors investigated the timeliness of breast cancer care at a comprehensive cancer center, focusing on factors influencing the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba160d8512f5bbef02b244c0eaed964
https://doi.org/10.1007/s10549-014-3124-2
https://doi.org/10.1007/s10549-014-3124-2
Autor:
Heather A. Jacene, Eren D. Yeh, Laura E.G. Warren, Beth Overmoyer, Meredith M. Regan, J Hirshfield-Bartek, Jennifer R. Bellon, Faina Nakhlis
Publikováno v:
Cancer Research. 72:P3-10
Background: While the survival of patients with inflammatory breast cancer (IBC) is dictated by the status of their distant metastases, local/regional control remains an important component of quality of life. We have sought to determine patterns of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ad83e6848c18d0416be7abf43d4f59e
https://doi.org/10.1158/0008-5472.sabcs12-p3-10-06
https://doi.org/10.1158/0008-5472.sabcs12-p3-10-06
Autor:
Susan Troyan, Tracy, J Hirshfield-Bartek, AH Partridge, EP Winer, S Come, Meghan E. Meyer, Karen Sepucha, Lidia Schapira, Shari Gelber, Monica Morrow
Publikováno v:
Cancer Research. 71:P4-11
Background: There has been an increasing prevalence of contralateral prophylactic mastectomy (CPM), particularly among younger women with breast cancer. There has been limited research evaluating patient preference, knowledge and decision-making rega
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f48cc19402e374364c095d539d93644
https://doi.org/10.1158/0008-5472.sabcs11-p4-11-10
https://doi.org/10.1158/0008-5472.sabcs11-p4-11-10
Autor:
Faina Nakhlis, Guillermo Peluffo, Kornelia Polyak, Sy Park, J Hirshfield-Bartek, Jennifer R. Bellon, Heather A. Jacene, Vanessa Almendro, Eren D. Yeh, Beth Overmoyer, Shaokun Shu
Publikováno v:
Cancer Research. 72:P4-06
Background: Inflammatory breast cancer (IBC) is a virulent subtype of locally advanced breast cancer that accounts for 1–5% of all breast cancers diagnosed in the United States. Conventional therapy for IBC (preoperative chemotherapy, mastectomy, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2472971019c7d45ed0ba4c7eeeb6f512
https://doi.org/10.1158/0008-5472.sabcs12-p4-06-01
https://doi.org/10.1158/0008-5472.sabcs12-p4-06-01